Assurance Health

Ladenburg Thalmann upgraded shares of Myriad Genetics, Inc. (NASDAQ: MYGN), premised on valuation, as it views that the sell thesis has largely played out. Q2 Largely In Line Analyst Kevin DeGeeter noted that the company reported second-quarter non-GAAP earnings of $0.26 per share on revenues...